Development and Commercialization of Licensed Products. As between the Parties, K▇▇▇▇▇ shall have sole control, authority, and discretion over the research, development, manufacture and commercialization of Licensed Products throughout the world, subject to Section 3.3. If K▇▇▇▇▇ ▇▇▇▇▇ any Licensed Product as part of a bundle, or as part of a combination therapy where K▇▇▇▇▇ has the right to sell and set the price of the other component of the combination therapy, then Kineta shall not disproportionately discount, in a manner inconsistent with the relative value of the components of such combination therapy or bundle, the pricing of the Licensed Product relative to the other components. K▇▇▇▇▇ shall not use any Licensed Product as a loss leader.
Appears in 2 contracts
Sources: Option and License Agreement (Yumanity Therapeutics, Inc.), Option and License Agreement (Yumanity Therapeutics, Inc.)